Congress Asset Management Co. Sells 180,874 Shares of Eli Lilly and Company $LLY

Key Points

• Congress Asset Management Co. significantly reduced its stake in Eli Lilly by selling 180,874 shares, leaving it with just 17,410 shares valued at approximately $13.57 million.
• Shares of Eli Lilly have shown a high volatility in the past year, with a 12-month low of $623.78 and a high of $937.00.
• Recent analyst ratings reflect varied opinions, with UBS Group lowering its price target from $1,050 to $895, but maintaining a "buy" rating.

Congress Asset Management Co. trimmed its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 91.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,410 shares of the company's stock after selling 180,874 shares during the quarter. Congress Asset Management Co.'s holdings in Eli Lilly and Company were worth $13,572,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of LLY. WestEnd Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $27,000. Citizens National Bank Trust Department lifted its holdings in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $40,000. Finally, Mascagni Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $43,000. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

LLY has been the subject of a number of recent analyst reports. UBS Group decreased their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Leerink Partners restated a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Berenberg Bank restated a "hold" rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Guggenheim cut their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. Finally, DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $939.61.

Eli Lilly and Company Price Performance

Shares of LLY opened at $724.73 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The company has a 50 day moving average of $734.15 and a two-hundred day moving average of $767.20. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a market cap of $685.93 billion, a price-to-earnings ratio of 47.37, a price-to-earnings-growth ratio of 0.99 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm's quarterly revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other news, Director Jamere Jackson acquired 200 shares of the business's stock in a transaction on Friday, August 8th. The stock was bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gabrielle Sulzberger acquired 117 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director directly owned 2,703 shares of the company's stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock valued at $2,894,841 over the last ninety days. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.